Clinical Trials Browser

Phase 1 × Has results × veliparib × Clear all

NCT03061188 2024-06-12

Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

Phase 1 Completed

15 enrolled 18 charts

Lymphoma, T-Cell, Lymphoma, Mantle-Cell

NCT02723864 2022-02-08

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Phase 1 Completed

53 enrolled 20 charts

Neoplasms